(English) Oryzon Announces First Subject Dosed in Phase I Healthy Volunteer Study Evaluating Oral Epigenetic drug ORY-2001 for Alzheimer’s Disease
Oryzon Genomics (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, today announced that the first subject has been dosed in a Phase I, randomized, double-blind, placebo-controlled single and multiple ascending dose program study to investigate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of its oral LSD1-MAOB dual selective inhibitor ORY-2001 in healthy subjects. The Phase I study is being conducted in Spain, pursuant to a Clinical Trial Application (CTA). With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in 1H 2017.
Oryzon announces First Subject Dosed in Phase I